Trial description:
A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
Contact name:
Dr Jean Abraham
Trial start date:
Friday, January 23, 2015
Trial end date:
Wednesday, January 23, 2019
Trial tumour type:
Breast
Show on Radiotherapy:
No
